Format

Send to

Choose Destination
Vox Sang. 2017 Oct;112(7):622-627. doi: 10.1111/vox.12553. Epub 2017 Sep 10.

Use of supplemental anti-HBc testing of donors showing non-discriminating reactive results in multiplex nucleic acid testing.

Author information

1
Blood Transfusion Research Institute, Korean Red Cross, Wonju, Korea.
2
Blood Service Headquarter, Korean Red Cross, Wonju, Korea.
3
Division of Human Blood Safety Surveillance, Korea Center for Disease Control and Prevention, Osong, Korea.

Abstract

BACKGROUND AND OBJECTIVES:

The Korean Red Cross began nucleic acid amplification testing (NAT) for HIV and HCV in February 2005, and added HBV NAT beginning in June 2012. The current NAT system utilizes a multiplex assay for simultaneous detection of HBV DNA, HCV RNA and HIV-1 RNA. For samples that are reactive in the multiplex assay, we do specific tests for each virus. However, there have been cases of non-discriminated reactive (NDR) results which appear to be the result of non-specific reactions or cross-contamination, although some cases are considered to arise from the presence of low levels of HBV DNA due to occult hepatitis B infection.

MATERIALS AND METHODS:

We examined the incidence of NDR results in previous donations of some NAT-reactive donors. Additionally, for those donors with NDR results, we performed an HBV core antibody (anti-HBc) assay.

RESULTS:

From November 2015 to March 2016, there were 408 NAT-reactive donors. Of these, nineteen HBV NAT-reactive donors showed a history of NDR results in the past donations. Seven donors showed NDR results more than once. Of 771 NDR donors, 362 (47·0%) were anti-HBc reactive.

CONCLUSION:

The NDR donors had a substantially higher rate of anti-HBc reactivity than other blood donors indicating that some with anti-HBc reactivity represent donors with occult HBV. Therefore, the incorporation of an anti-HBc testing for NDR donors could improve blood safety testing for the Korean Red Cross.

KEYWORDS:

blood safety; nucleic acid amplification testing; transfusion-transmissible infections

PMID:
28891069
DOI:
10.1111/vox.12553
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center